Clinical Trial Details
— Status: Suspended
Administrative data
NCT number |
NCT05647694 |
Other study ID # |
NEI-VNAV-2C |
Secondary ID |
|
Status |
Suspended |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
June 1, 2024 |
Est. completion date |
September 30, 2024 |
Study information
Verified date |
March 2024 |
Source |
Vortant Technologies, LLC |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The study will begin with an explanatory/training session where individuals with low vision
will learn to use the V-NAV (Vortant NAVigation tool) indoor navigation app, and will have
the opportunity to try it for a few representative tasks. The main activity includes a
take-home trial, an extended unstructured period to emulate the post-purchase experience of
users, during which participants will have the opportunity to use the V-NAV in their everyday
lives. Data will be collected from the users to measure the relative advantage of V-NAV
compared to the user's current indoor navigation method.
Description:
The introductory session, emphasizing real-world experiences, will involve a brief training
session followed by simulated navigation experiences in a convenient location to the users.
Participants will use V-NAV to record approximately 8 locations, then will be given
instructions to find these locations again. The V-NAV prototype's logging software will
measure distance walked and task time. Participants will complete a study-specific tool
covering the relevant attributes of the V-NAV prototype, as well as a standardized tool, the
NASA TLX (Task Load Index).
Subsequently, participants will complete a take-home trial, during which they will be
encouraged to use the V-NAV features regularly to support their everyday community navigation
activities. Participants will be contacted approximately weekly with a "check-in" to answer
questions and resolve any emergent technical problems. At the conclusion of the trial, a
product-specific tool and an appropriate standardized tool, the PIADS (Psychosocial Impact of
Assistive Devices Scale) will be administered.